We specialize in the research and development of targeting anti-tumor, anti-diabetic API and intermediates. Through the efforts of our R & D staff, our company applied for 9 patents in the year of 2017. Among which, there are 7 patents of targeting anti-tumor products, and 2 patents of targeting anti-diabetic products. Details are as follows:
Patents of targeting anti-tumor products:
| Cat.No. | Patent Name | Patent Number |
| 01 | A synthetic method of a Linagliptin intermediate | 201711472117.x |
| 02 | A synthetic method of a Sitagliptin intermediate | 201711471421.2 |
| 03 | A synthetic method of Palbociclib | 201711272258.7 |
| 04 | A synthetic method of Brigatinib intermediates | 201810104078.6 |
| 05 | A preparation method of a key intermediate of Alectinib | 201810131427.3 |
| 06 | A synthetic method of a key intermediate of Dasatinib | 201810139152.8 |
| 07 | A preparation method of a key intermediate of Lapatinib | 201810139151.3 |
| 08 | A synthetic method of Ipragliflozin | 201810143774.8 |
| 09 | A synthetic method of Niraparib | 201810147865.9 |
